A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Avicenna.ai SAS received U.S. FDA clearance for its Cina-Cspine algorithm, which uses machine learning technology to detect ...

Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Businesses can take proactive steps now to best position themselves for a competitive advantage in the face of the seismic shift these medications will have on the industry.

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining ...

A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining ...